Oculis Doses First Patient in Phase 3 PIONEER-1 Trial of Privosegtor for Optic Neuritis

Oculis announced that the first patient has been treated in the PIONEER-1 registrational trial evaluating Privosegtor for acute-onset optic neuritis, marking the start of the company’s late-stage clinical program for the investigational neuroprotective therapy. PIONEER-1 is the first of 2 registrational studies in Oculis’ PIONEER program, or "Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research." The trial is enrolling a broad population of patients with acute-onset optic neuritis, including those with and without multiple sclerosis (MS).

FDA Approves Outlook's Lytenava for Wet AMD

Eyetube

The CEO of Outlook Therapeutics discusses the FDA approval of wet AMD drug Lytenava; Roche receives a major boost in its efforts to commercialize wet AMD treatment Susvimo in Europe; and Glaukos reaches a milestone in its pivotal clinical study of the Preserflo MicroShunt. Learn more about your ad choices. Visit megaphone.fm/adchoices

PVRL: When “Uveitis” Is Not Uveitis

A steroid-responsive, uveitis-presenting phenotype was ultimately diagnosed as primary vitreoretinal lymphoma.

Andreas Theocharis, MD; Romy Bejjani, MD; and Erin E. Flynn, MD

Retina Today

KEY TAKEAWAYS The authors present a case of an immunocompromised patient with primary vitreoretinal lymphoma (PVRL) masquerading as chronic uveitis. The combination of bilateral vitritis, subretinal infiltrative-appearing lesions, and a central nervous system lesion should immediately raise suspicion for PVRL, even in a patient whose presentation may initially seem inflammatory. Intravitreal methotrexate and rituximab are effective local treatments for PVRL, whereas systemic methotrexate is commonly used when there is concurrent central nervous system disease. A 58-year-old man presented with severe bilateral vision loss and flashes. His VA was counting fingers at 3 ft OU. There was no relative afferent pupillary defect, and his IOPs were 18 mm Hg OD and 16 mm Hg OS. His medical history was notable for human immunodeficiency virus, and he was on antiretroviral therapy with a reported undetectable viral load. He also had abdominal diffuse large B-cell lymphoma treated with a regimen of etoposide, prednisone, vincristine, cyclophosphamide, and hydroxydaunorubicin, which had been in remission since 2017, as well as prior cryptococcal meningitis and prostate cancer, also in remission. His ocular history included glaucoma suspect, dry eye disease, and mild cataract in each eye. IMAGING AND WORKUP The anterior segment examination showed 2+ anterior chamber cells in each eye.

When a Minimally Invasive Procedure Fails

Iqbal Ike K. Ahmed, MD, FRCSC; Arsham Sheybani, MD; and Rachel G. Simpson, MD

Eyetube

Iqbal Ike K. Ahmed, MD, FRCSC, and Arsham Sheybani, MD, sit down with Rachel G. Simpson, MD, to reflect on the role of trabeculectomy in today’s glaucoma treatment landscape. They discuss the importance of minimally invasive surgical approaches but emphasize the need to keep trabeculectomy from becoming a lost art. They consider what deters surgeons from performing the traditional procedure today and how to prepare for the incoming volume of patients who have undergone MIGS or MIBS and may require trabeculectomy.

Featured Podcasts

Ophthalmology off the Grid

Open. Outspoken. It's Ophthalmology off the Grid—an honest look at controversial topics in the field.

View Feed

New Retina Radio

New Retina Radio is a place to hear stories about retina that are told nowhere else.

View Feed

Eyewire News: The Podcast

Get the latest information and breaking news in the ophthalmic field.

View Feed

Outlook Wins Appeal for Wet AMD Drug Candidate Lytenava

Eyetube

Outlook Therapeutics takes a major step forward in its plan to gain approval for wet AMD drug Lytenava; the first commercial FLIGHT procedures using the ViaLuxe Laser System are performed in Europe; and Oculus introduces a new AI-assisted tool designed to help clinicians evaluate MGD using meibography images. Learn more about your ad choices. Visit megaphone.fm/adchoices

Eyewire News

08.24.2026

Oculis Doses First Patient in Phase 3 PIONEER-1 Trial of Privosegtor for Optic Neuritis

08.24.2026

SightGlass Vision Reports 2 Million Children Worldwide Have Worn Dot Spectacle Lenses

08.21.2026

NICE Draft Guidance Recommends Against NHS Funding of Low-Dose Atropine for Childhood Myopia

08.21.2026

Harrow Reports Lower Patient Discomfort with Iheezo Versus Proparacaine After Intravitreal Injections

08.20.2026

FDA Expands TearCare's Indication to Include Improvement of Meibomian Gland Function

EyewireTV

08.19.2026

The Latest EyewireTV

Tamara R. Fountain, MD

Zubair Ansari, MD

Michelle Sun, MD, MPH

Stocks

Cataract

FDA Approves Outlook's Lytenava for Wet AMD

Seeing More of the Cornea

MIGS and Cataract Surgery

Addressing Inflammatory Dry Eye

Exploring Nd:YAG Vitreolysis After Cataract Surgery for Symptomatic Eyes

Genetically Predisposed to Capsular Bag Instability

08.21.2026

Harrow Reports Lower Patient Discomfort with Iheezo Versus Proparacaine After Intravitreal Injections

08.13.2026

Prevent Blindness Raises Concerns Over Proposed Head Start Vision Screening Changes

08.12.2026

Alfasigma Expands Presence in Europe with Acquisition of Nordic Pharma and the Lacrifill Canalicular Gel

08.11.2026

Omega Ophthalmics Closes $7 Million Financing, Schedules FDA Meeting for Gemini Refractive Capsule

Refractive

Getting More Out of the IOLMaster 700

Three Major Acquisitions Announced in Ophthalmology

Interventional Glaucoma: A Collaborative Care Model for the Future of Glaucoma Management

FDA Approves Outlook's Lytenava for Wet AMD

Beyond the Eyepieces

Rethinking the Drop with iDose TR: Patient Conversations

08.21.2026

Harrow Reports Lower Patient Discomfort with Iheezo Versus Proparacaine After Intravitreal Injections

08.13.2026

Prevent Blindness Raises Concerns Over Proposed Head Start Vision Screening Changes

08.12.2026

Alfasigma Expands Presence in Europe with Acquisition of Nordic Pharma and the Lacrifill Canalicular Gel

08.10.2026

WaveFront Dynamics Expands Scleral Lens Options Through Bausch + Lomb, WAVE Eye Care Integrations

Stay Updated

Follow Eyewire News

Retina

PVRL: When “Uveitis” Is Not Uveitis

FA Imaging in Behçet Disease

The Fellow Eye: Episode 6

Comparing Ocular AEs in Next-Gen Treatments

IRD Clinical Trial Endpoints: Lessons Learned

Therapies for IRDs: Moving Beyond Single-Gene Solutions

08.24.2026

Oculis Doses First Patient in Phase 3 PIONEER-1 Trial of Privosegtor for Optic Neuritis

08.19.2026

Eyconis Initiates First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet AMD

08.17.2026

Duravyu Misses Primary Endpoint in Phase 3 LUGANO Trial but Reduces Treatment Burden in Wet AMD

08.14.2026

Large UK Study Examines Impact of Anti-VEGF Treatment for DME on Progression to Proliferative Diabetic Retinopathy

Glaucoma

When a Minimally Invasive Procedure Fails

Where Plates and Fluidics Meet

The Buzz on Eyetube

Angle-Based MIGS for a Patient With Severe Glaucoma

How to Thrive as a New Fellow

Are Nonphysiologic IOP Targets Necessary?

08.21.2026

Harrow Reports Lower Patient Discomfort with Iheezo Versus Proparacaine After Intravitreal Injections

08.18.2026

Balance Ophthalmics Announces Medicare Pricing for FSYX Ocular Pressure Adjusting Pump

08.13.2026

Prevent Blindness Raises Concerns Over Proposed Head Start Vision Screening Changes

08.12.2026

Alfasigma Expands Presence in Europe with Acquisition of Nordic Pharma and the Lacrifill Canalicular Gel